1 min read
Fierce Biotech Summit 2024
Meet Veristat in Boston at the Fierce Biotech Summit Conference | September 30 - October 1 in Boston, Massachusetts
We...
1 min read
As you look to transition your compound into clinical trials, you need the right partner to guide your planning and decision-making. Whether you are preparing your IND/CTA, or you are looking to recruit patients quickly to get your early phase trials running, or just need medical writing or biostatistical support for your programs – Veristat can help.
We provide impactful solutions on both a full-service or functional service basis, including strategic regulatory guidance, clinical program design, and IND/CTA support through to successful regulatory approval.
We are pleased to announce that Montse Barceló Riera M.D., Vice President of Europe at Veristat, will be a speaker at the plenary session, The Patient Voice as a Starting and Ending Point for the Development of New Innovative Healthcare Solutions.
Panel Summary:
Moderator:
Jose Maria Gimenez Arnau, Chief Scientific & Medical Officer, ESTEVE Healthcare
Speakers:
Fulvio Capitanio, member of the World Parkinson Coalition 2023 Steering Committee, Barcelona
Carmen Rios Benton, Founder Doctomatic. Member Board Tech Barcelona
Begoña Nafría Escalera, Patient engagement & Research coordinator, Hospital Sant Joan de Déu, Barcelona. Coordinator eYPAGnet
Montse Barceló Riera, VP Europe Veristat
Veristat team members, Montse Barceló Riera MD, VP Europe, and Balma Gil, Business Development, will be at the venue, ready to listen to your needs and share Veristat’s expertise.
If you would like to meet us at BIOSPAIN 2023, feel free to contact us to arrange a meeting through the form.
Website: BIOSPAIN 2023
1 min read
Sep 13, 2024 Veristat Events
Meet Veristat in Boston at the Fierce Biotech Summit Conference | September 30 - October 1 in Boston, Massachusetts
We...
4 min read
Sep 13, 2024 Veristat Events
Don't miss Veristat’s plenary presentation at the World Orphan Drug Congress (WODC), Barcelona, Thursday, October 24th...